Alarum Technologies Ltd. has announced the details of its upcoming Annual General Meeting (AGM), scheduled for December 30, 2026, at 3:00 p.m. Israel time. This meeting is significant as it will allow shareholders to vote on key resolutions, including the reappointment of directors and the independent auditor. The filing reflects the company's ongoing commitment to transparency and shareholder engagement.
The announcement comes through a recent filing, which updates materials originally provided on November 5, 2026. The filing ensures that shareholders are well-informed about the agenda and the voting process for the upcoming meeting.
Background
Alarum Technologies Ltd., incorporated in Israel, operates within the prepackaged software sector (SIC: 7372). The company is listed on the Nasdaq under the ticker ALAR. As an accelerated filer, Alarum is subject to specific reporting requirements, which include regular updates to its shareholders.
What the Filing Says
The recent filing, dated November 9, 2026, states, "On November 5, 2026, Alarum Technologies Ltd. furnished a Report of Foreign Private Issuer on Form 6-K that included the proxy statement for its Annual General Meeting of Shareholders to be held on December 30, 2026." The filing confirms that all dates and times related to the meeting remain unchanged, along with the text of the proposed resolutions.
Impact
This update may affect shareholders, especially those holding American Depositary Shares (ADS) and ordinary shares, as they will have the opportunity to vote on important corporate matters. The reappointment of directors and auditors is crucial for the company's governance and operational integrity.
What's Next
The filing does not specify what happens next beyond the scheduled meeting. However, shareholders are encouraged to review the proxy statement and participate in the voting process.
Read Next
Alps Group Regains Compliance with Nasdaq Listing Standards
Ainos, Inc. Receives Nasdaq Delisting Notice Over Equity
Compass Therapeutics Receives Nasdaq Deficiency Notice
60 Degrees Pharmaceuticals Faces Nasdaq Delisting Risk
Biofrontera Inc. Faces Nasdaq Delisting Due to Low Stock Price
Senti Biosciences dismisses KPMG, appoints new auditor KNAV










